DOLF
IDA Acceptability Study (Fiji)
Assess the overall acceptability of the 3-drug treatment in the community as compared to the 2-drug treatment
IDA Acceptability Study (India)
Assess the overall acceptability of the 3-drug treatment in the community as compared to the 2-drug treatment
Triple Drug Therapy for LF
Comparison of safety profile and acceptability between triple drug therapy (IVM,DEC,ALB) and standard two-drug therapy (DEC, ALB), plus STH evaluation.
Triple Drug Therapy (India)
To determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB, DA) in infected and uninfected individuals in a community.
To compare the efficacy of IDA vs. DA administered in communities for clearance of Mf and filarial antigenemia (Ag) in cohort and effectiveness (prevalence) in community settings. To assess the presence and intensity of filarial infection on the frequency and severity of adverse events. To compare community acceptance of MDA with IDA vs. DA.
Randomized trial of Ivermectin/Albendazole vs. Ivermectin alone
Randomized clinical trail comparing treatment with Albendazole and Ivermectin to Ivermectin alone for Onchocerciasis.
Randomized trial of albendazole alone for LF in Cote d'Ivoire
Randomized Clinical Trial of Albendazole vs Ivermectin+Albendazole for lymphatic filariasis treatment and elimination.
Randomized trial of triple therapy (DEC/Alb/Iver) in Papua New Guinea
Randomized Clinical Trial comparing triple triple therapy of DEC/Alb/Iver vs. DEC/Alb alone
Analysis of MDA frequency and Brugia in Indonesia
Comparison of 2X vs. 1X per year MDA on Brugia with MDA of DEC/Alb , plus STH evaluation
Analysis of MDA for LF in loa endemic countries
Community MDA with 2X Alb alone for W. bancrofti in areas co-endemic for L. loa, plus STH evaluation